@article{879139468e4f4f669760ef3f8ee97cb3,
title = "STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus",
keywords = "Fibrosis, NASH, Phase 2 trails, Phase 3 trials, Selonserib",
author = "Rinella, {Mary E.} and Mazen Noureddin",
note = "Funding Information: Mary E. Rinella, MD: Consulting: Intercept Pharmaceuticals, Gilead Sciences, NGM Biopharmaceuticals, Enanta, Immuron, Fractyl, Prociento, Gelesis, Merck, Bristol-Myers Squibb, Metacrine, Viking Therapeutics, Allergan, Cymabay, Boehringer Ingelheim, Genentech, Sagimet Bio, Terns, Siemens and Novartis. Independent research grant funding from Novartis. Support in kind from Owl. Mazen Noureddin, MD; MHSc: MN has been on the advisory board for Gilead, Intercept, Pfizer, Novartis, Allergan, Blade, EchoSens North America, OWL, Terns, Simenes, Zydus, and Abbott; MN has received research support from Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Novartis, Shire and Zydus; MN is a minor shareholder or has stocks in Anaetos and Viking. ",
year = "2020",
month = jul,
doi = "10.1016/j.jhep.2020.04.034",
language = "English (US)",
volume = "73",
pages = "9--11",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "1",
}